Dihydroartemisinin (Artenimol) is an antimalarial drug.

HGC-27 cells viability:5.608 μM (48h), HeLa cells proliferation:24.74 ± 0.38 μM, SGC-7901 cells viability:5.191 μM (48h)

METHODS: Ovarian cancer cell lines ES2 and A2780 were treated with Dihydroartemisinin (0, 2.5, 5, 10, 20, 50, 100, and 200) for 48 hours, and the cell viability was detected by MTT assay.
RESULTS: Dihydroartemisinin inhibited the growth of ES2 (IC50=8.77 ± 1.23 µM) and A2780 cells (IC50=8.77 ± 1.23 µM). [1]
METHODS: Glioblastoma cell lines U87 and U251 were treated with Dihydroartemisinin (0.2, 2, 20, 50, 100, 200 and 600 µmol/L) for 24, 48, and 72 hours, and the cell viability was detected by CCK-8 assay.
RESULTS: Dihydroartemisinin inhibited the growth of U87 cells (IC50 values of 11.26 µM, 7.42 µM and 5.77 µM at 24, 48 and 72 hours, respectively) and U251 cells (IC50 values of 11.67 at 24, 48 and 72 hours, respectively) µM, 7.55µM, and 5.83µM). [2]
METHODS: Colorectal cancer cell lines SW620, DLD-1, HCT116, and COLO205 were treated with Dihydroartemisinin (0.2, 2, 20, 50, 100, 200, and 600 μmol /L) for 24 hours, and the cell viability was detected by MTT assay.
RESULTS: Dihydroartemisinin inhibited the proliferation of SW620 cells (IC50=35.96 ± 8.76 µM), DLD-1 cells (IC50= 15.08 ± 1.70 µM) and HCT116 cells (IC50=19.53 ± 1.24) µM), COLO205 cells (IC50=38.46 ± 4.15 µM). [3]

METHODS: To study the antitumor activity of Dihydroartemisinin, an orthotopic CRC mouse model of HCT116 cells or a xenograft mouse model of DLD-1 cells was administered with Dihydroartemisinin (15 mg/kg, 45 mg/kg).
RESULTS: In an orthotopic CRC mouse model of HCT116 cells, Dihydroartemisinin administered at a dose of 15 mg/kg or 45 mg/kg significantly inhibited tumor growth starting from the 18th day of treatment. In a xenograft mouse model of DLD-1 cells, Dihydroartemisinin significantly reduced tumor volume and weight. [3]
METHODS: To study the immunomodulatory effect of Dihydroartemisinin, healthy BALB/c mice were treated with Dihydroartemisinin (0.1 mg/mL) by gavage for 26 days.
RESULTS: Dihydroartemisinin significantly up-regulated c-Fos expression in plasma cells and regulatory T cells (Treg). [4]

BxPc3-RFP cells (3.5×104cells/well) were seeded in poly D-lysine-coated black, μClear 96-well plates with 0.2 ml medium. After 24 h, the cells were treated with dimethyl sulfoxide (DMSO) (control) or different concentrations (2.5, 10, 40, or 80 μM) of DHA dissolved in DMSO for 24, 48, and 72 h. At each time point, the fluorescence intensity emitted from cells was measured. (Only for Reference)